Santen Pharmaceutical Co., Ltd.

The company's Research and Development Center in Ikoma, Nara
Native name	参天製薬株式会社
Company type	Public KK
Traded as	TYO: 4536 OSE: 4536
Industry	Pharmaceutical
Founded	Osaka, Japan (1890 (1890))
Founder	Kenkichi Taguchi
Headquarters	Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan
Key people	Akira Kurokawa, (CEO and President)
Products	Pharmaceuticals Medical devices
Revenue	$ 2.429 billion (FY 2018) (¥ 243.0 billion) (FY 2018)
Net income	$ 175.661 million (FY 2012) (¥ 16.521 billion) (FY 2012)
Number of employees	3,805(consolidated) (as of March 31, 2018)
Website	Official website
Footnotes / references [1][2]

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社, Santen Seiyaku Kabushiki-gaisha), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.^[3]

The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.^[4] In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products.^[5]

Business locations

Santen has 3 plants located in Hōdatsushimizu, Ishikawa, in Tampere and in Suzhou, 21 subsidiary companies located in Japan, the US, the Netherlands, Finland, United Kingdom & Ireland, Spain, Switzerland, Italy, France,^[6] Germany, Sweden, China, South Korea, Taiwan, India, Thailand, Malaysia, the Philippines and Singapore. Its R&D center is located in Ikoma, Nara.^[7][8]